Stocks at record highs on stimulus prospects

by Jonathan Adams
Dow Jones

The Dow Jones Industrial Average gained 0.18%, the S&P 500 rose 0.55%, and the Nasdaq added 1.03%

Stocks finished at records for a second day Friday as investors assessed expectations for more economic stimulus following a weaker-than-expected U.S. jobs report.

A report in the Washington Post said West Virginia Sen. Joe Manchin opposed providing Americans with $2,000 stimulus checks, creating an obstacle for President-elect Joe Biden’s push to boost stimulus measures.

Biden has vowed that larger relief checks would be delivered to Americans if the Democrats won the Senate runoff elections in Georgia, which they did earlier this week.

The Dow Jones Industrial Average finished up 56 points, or 0.18%, to 31,097. The S&P 500 was up 0.55% to 3,824, and the Nasdaq gained 1.03% to 13,201.

The S&P 500 and Nasdaq also set record intraday highs during Friday’s session.

For the week, the Dow industrials rose 1.6%, the S&P 500 added 1.8% and the Nasdaq Composite tacked on 2.4%.

The U.S. lost 140,000 jobs in December, the first drop in employment since April, as Covid-19 cases surged and tighter restrictions were placed on people and businesses.

Hiring slowed in December amid another surge in coronavirus infections. Economists surveyed by FactSet had expected the U.S. to add 100,000 jobs in December, though many experts had predicted a contraction.

The unemployment rate in December held steady at 6.7%.

In one line: Grim and unlikely to get much better before the spring, said Ian Shepherdson, chief economist at Pantheon Macroeconomics.

Shepherdson said the jobs report tells a “story consistent with the surge in Covid cases in recent months, and the restrictions imposed to try to contain the pandemic.” He noted that leisure and hospitality jobs fell by 498,000 in December.

Boeing (BA) shares fell 1.3% to $210 after the jetmaker agreed to pay a $2.5 billion fine over fraud and conspiracy charges linked to its 737 MAX jet program.

A new study suggested the vaccine developed by Pfizer (PFE) and BioNTech (BNTX) could offer protection against mutations found in new, fast-spreading variants of the coronavirus that were discovered in the U.K. and South Africa.

The report, conducted by researchers from the University of Texas Medical Branch and supported by Pfizer and BioNTech, found that antibodies from vaccine recipients successfully fended off the virus in lab dishes. The study hasn’t yet been reviewed by experts.

Deaths in the U.S. from the coronavirus were at 367,635, according to Johns Hopkins University. The U.S. on Thursday reported a daily record of more than 4,000 deaths.

This article is for information purposes only.
Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.

Related News

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Know more